Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Treasury Shares (2016 - 2025)

Editas Medicine (EDIT) has disclosed Treasury Shares for 11 consecutive years, with $652267.0 as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares fell 74.32% to $652267.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $652267.0, a 74.32% decrease, with the full-year FY2024 number at $2.3 million, up 10.41% from a year prior.
  • Treasury Shares was $652267.0 for Q3 2025 at Editas Medicine, down from $923539.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.7 million in Q1 2024 to a low of $628732.0 in Q4 2021.
  • A 5-year average of $1.6 million and a median of $1.5 million in 2025 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: surged 138.43% in 2022, then plummeted 74.32% in 2025.
  • Editas Medicine's Treasury Shares stood at $628732.0 in 2021, then soared by 138.43% to $1.5 million in 2022, then skyrocketed by 40.56% to $2.1 million in 2023, then rose by 10.41% to $2.3 million in 2024, then tumbled by 71.96% to $652267.0 in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Treasury Shares are $652267.0 (Q3 2025), $923539.0 (Q2 2025), and $1.5 million (Q1 2025).